GleamWall
中文EN

VYGR Voyager Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1640266 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-19.8%
TTM net income YoY17.6%
TTM EPS YoY19.8%
Revenue 3-yr CAGR-45.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-450.1%
Net margin-416.3%
FCF margin-437.4%
EBITDA margin-435.3%

Returns

ROE-58.9%
ROA-44.9%
ROIC (approx.)-69.8%
Asset turnover0.11x

Leverage & solvency

Liabilities / assets23.7%
Debt / equity0.00x
Current ratio6.81x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.04x
Accruals ratio2.0%
Payout ratio—
Capex / revenue2.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$4.01M$3.17M$2.59M$15.34M$13.37M$5.20M$6.47M$6.28M
R&D expense$24.37M$22.04M$24.60M$35.95M$35.87M$31.33M$31.53M$35.58M
SG&A expense$6.07M$7.52M$8.26M$9.32M$8.09M$10.49M$9.64M$8.99M
Operating income-$26.42M-$26.39M-$30.27M-$29.93M-$30.59M-$36.62M-$34.69M-$38.30M
Pretax income-$24.68M-$24.45M-$27.92M-$27.42M-$27.81M-$33.37M-$30.98M-$33.90M
Income tax$18,000$20,000$14,000$9,000$83,000$15,000$37,000$584,000
Net income-$24.69M-$24.47M-$27.94M-$27.43M-$27.89M-$33.38M-$31.02M-$34.49M
EBITDA-$25.59M-$25.48M-$29.34M-$28.88M-$29.66M-$35.56M-$33.68M-$37.29M
EPS (basic)-0.40-0.40-0.47—-0.47-0.57-0.53—
EPS (diluted)-0.40-0.40-0.47—-0.47-0.57-0.53—
Weighted avg. shares (diluted)61.82M60.55M59.50M—58.80M58.67M58.35M—
Balance sheet
Cash & equivalents$48.41M$35.77M$43.31M$65.30M$50.74M$46.81M$77.63M$74.24M
Short-term investments$58.40M$80.57M$98.17M$131.15M$163.81M$171.65M$161.26M$195.32M
Receivables$4.02M$2.93M$1.49M$1.76M$3.19M$1.67M$1.62M$1.50M
Current assets$114.43M$125.23M$146.98M$202.69M$219.59M$227.89M$245.21M$276.81M
PP&E, net$9.77M$11.19M$12.22M$13.14M$13.29M$13.92M$13.93M$14.31M
Total assets$177.05M$197.75M$219.32M$252.28M$288.31M$322.10M$353.24M$393.05M
Current liabilities$16.81M$16.68M$17.45M$26.54M$35.49M$41.98M$40.21M$49.79M
Total liabilities$41.94M$43.38M$45.66M$56.20M$68.49M$78.16M$80.54M$93.29M
Shareholders' equity$135.11M$154.38M$173.67M$196.08M$219.82M$243.94M$272.70M$299.76M
Shares outstanding62.17M61.27M60.31M59.05M55.48M55.43M55.21M54.73M
Cash flow statement
Operating cash flow-$19.67M-$25.84M-$33.42M-$30.26M-$31.05M-$33.26M-$37.90M-$14.53M
Capital expenditure$0$0$14,000$626,000$207,000$1.10M$658,000$155,000
Free cash flow-$19.67M-$25.84M-$33.43M-$30.89M-$31.25M-$34.37M-$38.55M-$14.68M
Investing cash flow$29.27M$15.39M$8.10M$47.42M$34.89M$1.93M$41.20M-$27.20M
Financing cash flow$3.03M$2.91M$3.33M$136,000$85,000$513,000$82,000$574,000
Depreciation & amortization$836,000$908,000$932,000$1.05M$932,000$1.06M$1.01M$1.01M
Stock-based compensation$2.60M$2.60M$2.49M$3.52M$3.46M$4.13M$3.67M$3.74M

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.